Overall survival in Japanese patients with ER+/HER2- advanced breast cancer treated with first-line palbociclib plus letrozole

CONCLUSIONS: In this population of Japanese women with ER+/HER2- ABC, median OS was over 7 years with 1L PAL + LET, supporting the use of 1L PAL + endocrine therapy.TRIAL NUMBER: NCT04735367.PMID:37882974 | DOI:10.1007/s12282-023-01511-z

Source: Breast Cancer - October 26, 2023 Category: Cancer & Oncology Authors: Masato Takahashi Tomofumi Osako Hiroyuki Yasojima Kenichi Inoue Masahiro Kawashima Hideki Maeda Akemi Ichikawa Yasuaki Muramatsu Norikazu Masuda Source Type: research